Ibrutinib
Back to searchMolecule Structure
Scientific Name
Ibrutinib
Description of the Drug
Ibrutinib is an antineoplastic agent used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s Macroglobulinemia.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09053
http://www.drugbank.ca/drugs/DB09053
Brand Name(s)
Imbruvica
Company Owner(s)
Zydus Worldwide Dmcc, Pharmacyclics Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Tyrosine-protein kinase BTK | SINGLE PROTEIN | INHIBITOR | CHEMBL5251 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL201859 | |
| PharmGKB | PA166121346 | |
| DrugBank | DB09053 | |
| PubChem: Thomson Pharma | 49837088 | |
| PubChem | 24821094 | |
| LINCS | LSM-45830 | |
| Nikkaji | J2.980.554G | |
| PDBe | 1E8 | |
| BindingDB | 50357312 | |
| EPA CompTox Dashboard | DTXSID60893450 | |
| DrugCentral | 4810 | |
| Brenda | 213563 | |
| ChemicalBook | CB12515873 | |
| Guide to Pharmacology | 6912 | |
| rxnorm | IMBRUVICA | IBRUTINIB |
| ChEBI | 76612 | |
| ZINC | ZINC000035328014 |
